Loading…
Chinese pioneer of orthopedic and spine surgical robots that guide implant placement during surgery.
Chinese pioneer of orthopedic and spine surgical robots that guide implant placement during surgery.
Sells surgical robots to hospitals as large capital purchases, so sales depend on hospital equipment budgets and approvals in China. Surgeon training and procedure volumes decide whether installed robots keep being used and justify further purchases.
In one line: A Chinese Mazor Robotics/Stryker Mako for orthopedic surgery robotics.
Moat: narrow (IP / patents, regulatory licence). First-mover Chinese approvals and patented navigation robotics create an early lead.
Headquarters: Beijing, China · Founded: 2005 · Employees: 334
Size Tinavi Medical Technologies (688277.SS) is a China Health Care company (Medical Specialties) with a market value of $1.08B, the 2151st largest of 4,839 China companies the cockpit tracks. Shares closed at CN¥15.47 on 6 Nov 2026.
Performance Over six months the shares fell 30.0%, against -3.6% for the median peer and -16.4% for the China market (cap-weighted) — lowest of 20 in its peer set.
Growth Revenue fell 2.3% over the last twelve months (peer median +13.7%); the operating margin is -58.7% (peer median 7.2%).
Valuation It trades at 26.9× enterprise value to sales against a peer median of 3.4× (most expensive of 20).
Capital Return on invested capital runs 16.0 points below its cost of capital (8.5% WACC).
Next results Next results expected around 28 Apr 2027 (exchange calendar; dates can move).
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|---|
| Revenue | CN¥268M | CN¥279M | CN¥179M | CN¥209M | CN¥156M |
| Revenue growth | — | +56% | -15% | +34% | — |
| Gross profit | CN¥188M | CN¥156M | CN¥99.3M | CN¥121M | CN¥85.1M |
| EBITDA | n/a | -CN¥131M | -CN¥115M | -CN¥167M | -CN¥125M |
| Net income | -CN¥164M | -CN¥183M | -CN¥121M | -CN¥156M | -CN¥111M |
| Free cash flow | -CN¥203M | -CN¥85.0M | -CN¥135M | -CN¥395M | -CN¥144M |
| Capital expenditure | CN¥29.6M | CN¥29.7M | CN¥36.7M | CN¥221M | CN¥59.6M |
| Total debt | CN¥207M | CN¥197M | CN¥199M | CN¥220M | CN¥98.4M |
The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.
| Company | Market cap | 6M return | Revenue growth | Op. margin | EV / Sales | Req g |
|---|---|---|---|---|---|---|
| Tinavi Medical Technologies 688277.SS | $1.08B | -30% | -2% | -59% | 26.9× | n/a |
| Medtronic MDT | $130B | +35% | +10% | 20% | 4.0× | 8.6% |
| Stryker SYK | $124B | +14% | +8% | 25% | 5.2× | 10.6% |
| Beijing Balance Medical Technology 688198.SS | $1.47B | -26% | +10% | 28% | 15.0× | 22.6% |
Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.
| Measure | 688277.SS | Peer median | Rank in peer set |
|---|---|---|---|
| 1-month return | +4.1% | +0.3% | 9th highest of 21 |
| 6-month return | -30.0% | -3.6% | lowest of 20 |
| Distance from 52-week high | -46.8% | -33.6% | 6th lowest of 21 |
| Revenue growth (TTM) | -2.3% | +13.7% | 3rd lowest of 20 |
| Operating margin | -58.7% | 7.2% | 2nd lowest of 20 |
| EV / Sales | 26.9× | 3.4× | most expensive of 20 |
| ROIC minus cost of capital | -16.0 pp | -4.8 pp | 6th lowest of 20 |
| Company | Market | Market cap | 6M return | Revenue growth | Op. margin | EV / Sales | Req g | Delivered g |
|---|---|---|---|---|---|---|---|---|
| Tinavi Medical Technologies 688277.SS | China | $1.08B | -30% | -2% | -59% | 26.9× | n/a | n/a |
| INKON Life Technology 300143.SZ | China | $1.08B | -14% | +22% | 12% | 3.4× | 12.4% | +12.9% |
| PHC 6523.T | Japan | $1.09B | +36% | +3% | 7% | 1.0× | -2.3% | +3.6% |
| SI-BONE SIBN | United States | $1.09B | +98% | +14% | -8% | 4.5× | n/a | n/a |
| Freenome FRNM | United States | $1.09B | n/a | n/a | n/a | n/a | n/a | n/a |
| L&C BIO 290650.KS | South Korea | $1.07B | -17% | +53% | 17% | 12.8× | n/a | n/a |
| Amoy Diagnostics 300685.SZ | China | $1.10B | -14% | +7% | 34% | 5.2× | 6.5% | +10.3% |
| IRadimed IRMD | United States | $1.10B | 0% | +11% | 32% | 11.7× | 19.1% | +21.5% |
| Beijing Wandong Medical Technology 600055.SS | China | $1.11B | -27% | -11% | -33% | 3.4× | n/a | n/a |
| Edan Instruments 300206.SZ | China | $1.05B | -19% | +14% | 17% | 2.7× | 7.7% | -2.9% |
| Integra LifeSciences IART | United States | $1.04B | -4% | +1% | 12% | 1.6× | 5.2% | +3.6% |
| Beijing Strong Biotechnologies 300406.SZ | China | $1.13B | +1% | -4% | 36% | 5.8× | 1.5% | +9.9% |
| Ceribell CBLL | United States | $1.03B | +32% | +31% | -70% | 8.6× | n/a | n/a |
| Mingyue Optical Lens 301101.SZ | China | $1.14B | +6% | +14% | 25% | 6.8× | 10.0% | +8.8% |
| Alphatec ATEC | United States | $1.15B | -1% | +15% | -3% | 2.0× | n/a | n/a |
| Inno Laser Technology 301021.SZ | China | $1.16B | -18% | +17% | 9% | 12.7× | 53.9% | +8.6% |
| Tandem Diabetes Care TNDM | United States | $1.18B | +9% | +4% | -4% | 1.4× | n/a | n/a |
| Castle Biosciences CSTL | United States | $993M | +64% | +3% | -9% | 2.1× | n/a | n/a |
| PROCEPT BioRobotics PRCT | United States | $1.18B | -19% | +23% | -34% | 3.0× | n/a | n/a |
| Artivion AORT | United States | $985M | -20% | +16% | 7% | 2.8× | n/a | n/a |
| HOB Biotech 688656.SS | China | $972M | -22% | +6% | 7% | 15.6× | 40.1% | +12.4% |